A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
Clinical trial NCT04786028 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04786028
- Sponsor
- Canadian Myeloma Research Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-08
- Primary completion
- 2026-03-01
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.